8-K: Arcus Biosciences Q3 2025: Casdatifan, Pipeline & Cash

Arcus Biosciences reported Q3 2025 financial results and provided pipeline updates, highlighting strong casdatifan data and a new inflammatory disease portfolio.

Summary

• Casdatifan, a HIF-2a inhibitor, demonstrated a median progression-free survival (mPFS) of 12.2 months and an 18-month landmark PFS of 43% in a pooled analysis of 121 patients with late-line kidney cancer.
• The 100mg once-daily casdatifan cohort showed a 35% confirmed overall response rate (ORR) with mPFS not yet reached after over 12 months of median follow-up.
• Domvanalimab plus zimberelimab and chemotherapy achieved a median overall survival (OS) of 26.7 months in Arm A1 of the Phase 2 EDGE-Gastric study for first-line upper gastrointestinal adenocarcinomas.
• Enrollment for the Phase 3 PRISM-1 trial of quemliclustat in pancreatic cancer was completed within 12 months of study initiation.
• Arcus unveiled five new preclinical programs targeting inflammatory and autoimmune diseases, with the first, an MRGPRX2 small-molecule inhibitor, expected to enter the clinic in 2026.
• Cash, cash equivalents, and marketable securities stood at $841 million as of September 30, 2025, providing a cash runway through initial pivotal readouts for domvanalimab, quemliclustat, and casdatifan.
• Total revenues for Q3 2025 were $26 million, down from $48 million in Q3 2024, primarily due to lower license revenue from Taiho and reduced Gilead collaboration revenue.
• Research and Development (R&D) expenses increased to $141 million in Q3 2025 from $123 million in Q3 2024, driven by late-stage programs.
• Net loss for Q3 2025 was $135 million, compared to $92 million for Q3 2024.

Sentiment

Score: 6

Explanation: While financial results show increased losses and decreased revenue, the strong clinical data for casdatifan and domvanalimab, along with the expansion into inflammatory diseases and a solid cash runway, provide significant positive momentum. The temporary pause in one study is a minor setback compared to the overall pipeline progress.

Positives

• Casdatifan demonstrated a best-in-class profile with 12.2 months mPFS and 43% 18-month landmark PFS in late-line kidney cancer, outperforming the only marketed HIF-2a inhibitor.
• The 100mg once-daily casdatifan cohort showed a 35% confirmed ORR and mPFS not reached, indicating strong efficacy.
• Domvanalimab combination therapy achieved a median OS of 26.7 months in upper GI adenocarcinomas, exceeding clinical benefit requirements.
• Taiho exercised its option for an exclusive license to casdatifan in Japan and certain Asian territories, triggering an option payment and future milestones/royalties.
• Rapid enrollment completion for the Phase 3 PRISM-1 trial of quemliclustat within 12 months.
• Introduction of a new portfolio of five programs for inflammatory and autoimmune diseases, diversifying the pipeline.
• Strong cash position of $841 million, providing a cash runway through multiple Phase 3 readouts, including PEAK-1.
• Expectation for R&D expenses to decline starting Q4 2025 due to decreasing costs for the domvanalimab Phase 3 program.

Negatives

• Revenues decreased to $26 million in Q3 2025 from $48 million in Q3 2024, primarily due to lower license and collaboration revenues.
• Net loss increased to $135 million in Q3 2025 from $92 million in Q3 2024.
• Research and Development (R&D) expenses increased by $18 million year-over-year to $141 million.
• Temporary pause in recruitment for the eVOLVE-RCC02 study (casdatifan + volrustomig) due to observations of potential immune-mediated adverse events, although none exceeded Grade 3.

Risks

• Preliminary and interim data are not guarantees that future data will be similar.
• Unexpected emergence of adverse events or other undesirable side effects in investigational products.
• Difficulties or delays in initiating or conducting clinical trials due to regulatory processes, subject enrollment, or manufacturing/supply issues.
• Difficulties associated with the management of collaboration activities.
• Changes in the competitive landscape for Arcus's programs.
• Inherent uncertainty associated with pharmaceutical product development and clinical trials.

Future Outlook

Arcus Biosciences anticipates a steady cadence of key data events in 2026 and beyond, including additional analyses for casdatifan monotherapy in late-line ccRCC in 1H 2026, more mature data for casdatifan plus cabozantinib in mid-2026, and initial data for early-line casdatifan cohorts in 2H 2026. Data from the Phase 3 STAR-221 study for domvanalimab are expected in 2026. The company aims to initiate a Phase 3 study in early-line ccRCC in 2H 2026 and expects to select development candidates for at least three new inflammatory/autoimmune programs within 12 months, with the first, an MRGPRX2 inhibitor, entering the clinic in 2026. R&D expenses are projected to decline starting in Q4 2025.

Management Comments

• "Data from the ARC-20 study demonstrate that casdatifan has a best-in-class profile, based on a meaningfully higher response rate and longer PFS relative to data for the only marketed HIF-2a inhibitor." Terry Rosen, Ph.D., chief executive officer of Arcus.
• "With our global Phase 3 PEAK-1 study now enrolling, and based on the encouraging, emerging data from cohorts evaluating casdatifan-based regimens in early-line settings, we are extremely excited about the potential for casdatifan to be a transformative therapy in clear cell renal cell carcinoma (ccRCC)." Terry Rosen, Ph.D., chief executive officer of Arcus.
• "We remain well capitalized and funded through readout of multiple Phase 3 trials, and we are looking forward to a steady cadence of key data events in 2026 and beyond." Terry Rosen, Ph.D., chief executive officer of Arcus.

Industry Context

The oncology and autoimmune/inflammatory disease sectors are highly competitive, with significant unmet needs. Arcus's focus on HIF-2a inhibition (casdatifan) in kidney cancer positions it in a growing area, especially with the potential for a 'best-in-class' profile compared to existing therapies like the marketed HIF-2a inhibitor. The TIGIT pathway (domvanalimab) remains a key area of interest in immuno-oncology, and positive OS data in gastric cancer could differentiate Arcus. The expansion into inflammatory and autoimmune diseases with multiple preclinical programs indicates a strategic diversification, tapping into large markets with high demand for novel treatments. The temporary pause in the eVOLVE-RCC02 study highlights the inherent safety challenges in developing combination immunotherapies.

Comparison to Industry Standards

• Casdatifan's mPFS of 12.2 months and 18-month landmark PFS of 43% in late-line ccRCC are presented as 'meaningfully higher' than published data for the only marketed HIF-2a inhibitor (e.g., belzutifan).
• Domvanalimab plus zimberelimab and chemotherapy's median OS of 26.7 months in first-line upper GI adenocarcinomas is stated to be 'well beyond what would be required to demonstrate clinically meaningful benefit over standard of care in this setting.' This compares favorably to typical standard-of-care chemotherapy regimens (12-15 months OS) and PD-1 inhibitor combinations (15-20 months OS) in gastric cancer.

Related Party Transactions

• Gilead collaboration: Arcus and Gilead are co-developing zimberelimab, domvanalimab, and quemliclustat. Gilead has option rights to inflammation programs, with potential milestone and royalty payments to Arcus.
• Taiho collaboration: Taiho exercised its option for an exclusive license to casdatifan in Japan and certain territories in Asia, involving an option payment, milestone payments, and royalty payments to Arcus.

Stakeholder Impact

• Shareholders: Positive clinical data for key pipeline assets (casdatifan, domvanalimab) could increase shareholder value. Increased net loss and decreased revenue might be a concern, but the strong cash runway mitigates immediate financial risk. The temporary pause in one study introduces some uncertainty.
• Patients: Promising data for casdatifan in kidney cancer and domvanalimab in upper GI adenocarcinomas offer hope for new, potentially more effective treatment options. The expansion into inflammatory and autoimmune diseases could also benefit patients in those areas.
• Employees: Continued pipeline advancement and diversification suggest stability and growth opportunities.
• Partners (Gilead, Taiho, AstraZeneca): Continued collaboration and successful program advancement strengthen these partnerships. Taiho's exercise of the casdatifan option is a positive for that relationship. The eVOLVE-RCC02 pause requires close coordination with AstraZeneca.

Next Steps

• Continue monitoring participants in the eVOLVE-RCC02 study to characterize the safety profile of the casdatifan + volrustomig combination.
• Engage in discussions with health authorities regarding next steps for the eVOLVE-RCC02 study.
• Complete enrollment for ARC-20 early-line cohorts by the end of 2025.
• Report additional analyses from ARC-20 casdatifan monotherapy cohorts in late-line ccRCC in 1H 2026.
• Report more mature data from ARC-20 casdatifan plus cabozantinib cohort in mid-2026.
• Report initial data from one or more ARC-20 cohorts evaluating casdatifan in early-line settings in 2H 2026.
• Report data from the Phase 1b portion and make a go-no-go decision on the Phase 3 portion of eVOLVE-RCC02 in 2H 2026.
• Initiate a Phase 3 study in early-line ccRCC in the second half of 2026.
• Report data from the ongoing Phase 3 STAR-221 study in 2026.
• Select development candidates for at least three new inflammatory and autoimmune programs within the next 12 months.
• Advance the MRGPRX2 small-molecule inhibitor into the clinic in 2026.

Key Dates

Recommendation

The filing presents a mixed bag. On the positive side, the clinical data for casdatifan and domvanalimab are very encouraging, suggesting potential best-in-class or highly competitive profiles, which is crucial for a clinical-stage biopharmaceutical company. The expansion into inflammatory and autoimmune diseases also adds long-term value and diversification. The company's cash position is strong enough to fund operations through key pivotal readouts. However, the financial results show a significant increase in net loss and a decrease in revenue, which are concerning. The temporary pause in the eVOLVE-RCC02 study, while not critical, introduces a minor setback and uncertainty. Given the strong clinical progress balanced against the worsening financials and a minor clinical delay, a 'hold' recommendation is appropriate. Investors should await further clinical data readouts and monitor financial performance closely.

Keywords

Arcus Biosciences, RCUS, financial results, Q3 2025, pipeline update, casdatifan, HIF-2a inhibitor, kidney cancer, ccRCC, domvanalimab, TIGIT antibody, zimberelimab, PD-1 antibody, upper GI adenocarcinoma, quemliclustat, CD73 inhibitor, pancreatic cancer, inflammatory diseases, autoimmune diseases, clinical trials, biopharmaceutical, oncology, drug development, Taiho, AstraZeneca, Gilead